• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

    4/29/25 5:15:09 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    DEFA14A 1 pmn-20250428xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14 (a) of the

    Securities Exchange Act of 1934 (Amendment No.  )

    ​

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    PROMIS NEUROSCIENCES INC.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person (s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11.


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V74665-P30660 PROMIS NEUROSCIENCES INC. ONE BROADWAY, SUITE 1400 CAMBRIDGE, MA 02142 USA PROMIS NEUROSCIENCES INC. 2025 Annual Meeting Vote by June 10, 2025 11:59 PM ET You invested in PROMIS NEUROSCIENCES INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 12, 2025. Vote Virtually at the Meeting* June 12, 2025 10:00 am, Eastern Time Virtually at: www.virtualshareholdermeeting.com/PMN2025 Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V74666-P30660 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors To elect seven directors, each to serve until the next annual meeting of shareholders and until his or her respective successors is duly elected and qualified, or such director’s earlier death, resignation, or removal. 1a. Eugene Williams For 1b. Neil Cashman, M.D. For 1c. Patrick D. Kirwin For 1d. Joshua Mandel-Brehm For 1e. Maggie Shafmaster, Ph.D., J.D. For 1f. Neil K. Warma For 1g. William Wyman For 2. Appointment of Auditors To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To approve the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $PMN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProMIS Neurosciences Announces Private Placement Financing

      TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has entered into a purchase agreement (the "Purchase Agreement") with an existing institutional and accredited investor to issue and sell an aggregate of approximately $2.4 million of warrants (the "Warrants"). The Warrants were sold at a price of $0.1875 per share through a privat

      7/22/25 7:01:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

      CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) --  ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor. The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the "Pre-Funded Warrants") to purchase 984,736 common shares, no par value (the "Common Shares").  T

      7/22/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

      CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease (AD). The FDA Fast Track program is intended to accelerate the development of therapies that aim to address serious conditi

      7/21/25 8:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gordon Michael S sold 93,223 shares, closing all direct ownership in the company (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      7/2/25 4:15:22 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mandel-Brehm Josh

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      6/16/25 5:23:07 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kirwin Patrick D.

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      6/16/25 5:11:49 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/24/24 6:56:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/18/24 4:15:05 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    SEC Filings

    See more
    • ProMIS Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

      7/22/25 4:30:27 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by ProMIS Neurosciences Inc.

      424B5 - ProMIS Neurosciences Inc. (0001374339) (Filer)

      7/22/25 4:21:41 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

      8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

      7/22/25 6:30:21 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    See more
    • ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

      5/14/24 4:01:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

      4/1/24 4:15:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences, Inc. Announces Leadership Transition

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

      1/3/24 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 4:56:13 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProMIS Neurosciences Inc.

      SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 3:36:04 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/6/24 4:15:57 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care